Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (NASDAQ: CDXS) generates news primarily around its enzymatic technologies for therapeutics manufacturing and the development of its ECO Synthesis® / ECO Synthesis™ manufacturing platform. The company’s announcements frequently highlight progress in applying enzyme-based processes to small molecule pharmaceuticals manufacturing and nucleic acid synthesis, as well as steps toward enabling scaled manufacture of RNAi therapeutics, including siRNA and other oligonucleotides, through enzymatic routes.
News about Codexis often covers financial results and business updates, where the company reports on revenues, product gross margins, research and development spending, and strategic priorities. These releases typically include commentary on the performance of its Pharma Biocatalysis business, the status of ECO Synthesis-related activities, and the company’s cash position and funding plans as disclosed in its quarterly and annual reporting cycles.
Another recurring theme in Codexis news is collaborations and evaluation agreements with organizations involved in oligonucleotide therapeutics. The company has announced agreements with CDMOs and CRDMOs such as Nitto Denko Avecia and Axolabs to evaluate the ECO Synthesis manufacturing platform for therapeutic siRNA and other oligonucleotides. These updates describe how partners assess Codexis’s enzymatic approach and indicate that such evaluations may lead to licensing discussions and broader adoption.
Codexis also issues news about infrastructure and strategic initiatives, including the signing of a lease for a GMP manufacturing facility in Hayward, California, intended to support GMP manufacturing of siRNA and other oligonucleotides using ECO Synthesis. Additional releases detail organizational changes, leadership transitions, workforce streamlining aligned with an enhanced focus on ECO Synthesis, and participation in industry conferences such as TIDES USA and TIDES Europe, where Codexis and its collaborators present data on enzymatic manufacturing technologies.
Investors and observers who follow CDXS news can use this stream of updates to monitor Codexis’s progress in advancing enzyme-based manufacturing platforms, its relationships with manufacturing partners, and its evolving strategic focus within therapeutics manufacturing.
Codexis (NASDAQ: CDXS), an enzyme engineering company, announced its participation in the TD Cowen 2nd Annual Sustainability Week from May 21-23, 2024. The company will join a panel on May 22, 2024, to discuss “Sustainable API Manufacturing” focusing on the benefits of enzymatic synthesis in creating small molecule and siRNA therapeutics. The event will be live-streamed and available for replay on the Codexis website.
On May 14, 2024, Codexis (NASDAQ: CDXS) announced a significant milestone in enzymatic synthesis at the TIDES USA annual meeting. The company successfully synthesized a full-length oligonucleotide via its ECO Synthesis™ platform, offering an alternative method for RNA-based therapeutics production. This platform demonstrated coupling efficiency greater than 98% and minimized impurities compared to conventional methods. Codexis also launched RNA Ligase Screening and Optimization Services, aimed at improving RNA synthesis efficiency and scalability. This development could potentially lower manufacturing costs and enhance the quality and yield of RNA therapeutics.
Codexis, Inc. (NASDAQ: CDXS) reported a 32% increase in total revenue for Q1 2024, with product revenue up 14%. The company secured its first substantial order for dsRNA Ligase from a large pharma customer. Codexis also received a $40 million loan facility agreement with Innovatus, strengthening its cash position. Additionally, the company entered into an exclusive global license agreement with Roche Sequencing Solutions, Inc. Codexis expects to achieve significant milestones in enzymatic synthesis and ECO Synthesis™ platform development, with a focus on DNA ligation. Financially, the company saw positive growth in total and product revenues, improved product gross margin, and reduced R&D and SG&A expenses. The net loss decreased compared to Q1 2023, with cash reserves to support operations until positive cash flow is expected in 2026. Codexis reaffirmed its 2024 financial guidance, anticipating growth across product and R&D revenues.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.